Results 151 to 160 of about 3,391 (207)

Antiamnesic and Neurotrophic Effects of Parkia biglobosa (Jacq.) R. Br (Fabaceae) Aqueous Extract on In Vivo and In Vitro Models of Excitotoxicity. [PDF]

Behav Neurol
Kandeda AK, Foutse LY, Tongoue C, Djientcheu JP, Dimo T.   +4 more
europepmc   +1 more source

Efficacy and safety of anti-inflammatory drug-assisted treatment of symptoms in patients with schizophrenia: a meta-analysis. [PDF]

BMC Psychiatry
Li H, Shen H, Duan X, Guo M, Liu X.
europepmc   +1 more source

Alzheimer's Disease: The Current and Emerging Treatment Approaches. [PDF]

Behav Neurol
Pang R, Jia Q, Ma C, Li T, Bi W, Wang H, Liu R, Chen P, Lee ES, Jiang HB.   +9 more
europepmc   +1 more source

Effectiveness of piracetam in cortical myoclonus

Movement Disorders, 1993
Twenty-one patients with disabling spontaneous, reflex, or action myoclonus due to various causes, who had shown apparent clinical improvement on introduction of piracetam, entered a placebo-controlled double-blind crossover trial of piracetam (2.4-16.8 ...
Peter Brown, M J Steiger, John C Rothwell   +2 more
exaly   +2 more sources

Treatment of Acute Ischemic Stroke With Piracetam

Stroke, 1997
Background and Purpose Piracetam, a nootropic agent with neuroprotective properties, has been reported in pilot studies to increase compromised regional cerebral blood flow in patients with acute stroke and, given soon after ...
Jacques De Reuck, Jean-Marc Orgogozo, Peter Paul De Deyn   +2 more
exaly   +2 more sources

Piracetam improves mitochondrial dysfunction following oxidative stress

British Journal of Pharmacology, 2006
1.--Mitochondrial dysfunction including decrease of mitochondrial membrane potential and reduced ATP production represents a common final pathway of many conditions associated with oxidative stress, for example, hypoxia, hypoglycemia, and aging.
Uta Keil, Isabel Scherping, Susanne Hauptmann   +2 more
exaly   +2 more sources

Piracetam treatment in patients with cognitive impairment

General Hospital Psychiatry, 2013
Piracetam is a cognitive-enhancing agent that is used for the treatment of cognitive impairments of various etiologies. Little is known about its side effect profile, especially in those with psychiatric illness.
Bharath Holla, Shivarama Varambally, Dhanya Raveendranathan   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Antimyoclonic Action of Piracetam

Clinical Neuropharmacology, 1986
Five patients with myoclonus were treated with oral piracetam (8-9 g/day). All patients had action-sensitive and/or stimulus-sensitive myoclonus and enhanced amplitude of somatosensory evoked potentials. Piracetam produced a marked reduction of the myoclonus in the five subjects without side effects.
J A, Obeso, J, Artieda, M R, Luquin, J, Vaamonde, J M, Martínez Lage   +4 more
openaire   +2 more sources

Piracetam in Elderly Motorists

Pharmacopsychiatry, 1991
101 elderly motorists with reduced reaction capacity were examined under real traffic conditions with regard to their driving ability. They were given a daily dose of 4.8 g piracetam or placebo over a six-week period in a randomised double-blind study.
U, Schmidt, D, Brendemühl, K, Engels, N, Schenk, E, Ludemann   +4 more
openaire   +2 more sources

Piracetam and Piracetam-Like Drugs

Drugs, 2010
There is an increasing interest in nootropic drugs for the treatment of CNS disorders. Since the last meta-analysis of the clinical efficacy of piracetam, more information has accumulated. The primary objective of this systematic survey is to evaluate the clinical outcomes as well as the scientific literature relating to the pharmacology ...
Andrei G, Malykh, M Reza, Sadaie
openaire   +2 more sources